TEMISIS
- Company typePrivate
- Founded2017
- HeadquartersVandoeuvre-lès-nancy, France
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
TEMISIS firmographics
Firmographics- Name
- TEMISIS
- Legal name
- TEMISIS THERAPEUTICS
- Website
- https://temisis.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
TEMISIS industry classification
Industry- Product category
- Inflammatory Disease Therapeutics
- NAICS
- Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)
- akta.pro secondary industry
- Rare Dermatology Disorder Therapies (HLAIAIAM)
Keywords
Where TEMISIS is headquartered
LocationHeadquarters
- HQ city
- Vandoeuvre-lès-nancy
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
TEMISIS business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Marketing channels1 record
TEMISIS product offering
Product offeringCore offering
Temisis Therapeutics is a pre-clinical biotechnology company developing proprietary small-molecule drug candidates for the treatment of inflammatory diseases, with a primary focus on psoriasis. Its lead program, TEM1657, targets the Th17/23 axis through both topical and oral routes, offering rapid efficacy and a best-in-class safety profile compared to existing corticosteroids and oral treatments such as Apremilast.
Product overview
TEMISIS Therapeutics is a pre-clinical biotechnology company developing novel small-molecule drugs for inflammatory diseases. The company's core product is TEM1657, a proprietary compound targeting the Th17/23 axis for the treatment of psoriasis, available in both topical and oral formulations. The pipeline includes ongoing pre-clinical programs focused on inflammatory conditions with high unmet medical needs.
Differentiator
Problem solved
Functional benefit
Products and services
- TEM1657 (lead compound program)
Quantifiable outcome
- Topical application: 4-day healing process as efficient as corticosteroid treatment Dermoval (0.05% Clobetasol)
- +2 more outcomes
Companies that use TEMISIS
Customer profileSegments1 record
Ideal customer profiles1 record
TEMISIS technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
TEMISIS partnerships and signals
Strategic signalScale indicators1 record
Recent moves4 records
Expansion highlights4 records
TEMISIS competitors and assessment
Company assessmentBroad incumbents
- Amgen: Global biopharma with inflammation/dermatology franchise (Otezla, Enbrel, Tezspire) and active IL-23 development. Broad incumbent with overlapping target biology and commercial reach in psoriasis.
- AbbVie: Global biopharma leader with Skyrizi (risankizumab, IL-23) and Humira in psoriasis/psoriatic arthritis. Broad incumbent setting the competitive standard Temesis would need to differentiate against.
- Novartis: Global pharma with Cosentyx (secukinumab, IL-17A) as a flagship psoriasis franchise. Major incumbent whose biologic franchise defines the Th17-axis competitive landscape Temesis is targeting.
- Bristol Myers Squibb: Acquired Celgene and now markets Otezla (Apremilast) — the oral psoriasis comparator Temesis benchmarks against. Broad incumbent representing the existing oral standard of care in psoriasis.
Direct peers
- Aristea Therapeutics: Clinical-stage biotech developing immunology and inflammation therapeutics for serious inflammatory diseases. Comparable pre-clinical-to-clinical inflammation biotech focused on similar unmet needs.
- AnaptysBio: Clinical-stage immunology biotech developing antibody and small-molecule therapeutics for inflammatory and autoimmune diseases, including psoriasis. Directly comparable pre-clinical-to-clinical inflammation biotech with a similar target-class focus.
- Ventyx Biosciences: Clinical-stage small-molecule immunology biotech with pipeline candidates in psoriasis and other inflammatory indications. Directly comparable small-molecule immunology developer with overlapping target mechanisms.
- Aclaris Therapeutics: Clinical-stage small-molecule biotech focused on immuno-inflammatory and dermatological diseases. Comparable as a small-molecule-focused dermatology/inflammation developer targeting similar patient populations.
- Dice Molecules: Pre-clinical/early-stage small-molecule biotech developing oral IL-17 modulators for inflammatory diseases including psoriasis. Direct mechanistic parallel to Temesis's Th17/23 small-molecule approach (acquired by Eli Lilly in 2023, validating the space).
Emerging players
- Sareum Holdings: Early-stage UK-based small-molecule drug discovery company developing kinase inhibitors for autoimmune and inflammatory diseases. Comparable emerging small-molecule inflammation developer with similar pre-clinical profile.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
TEMISIS social profiles
Digital presenceTEMISIS compliance and trust
Trust signalCompliance1 record
TEMISIS financial estimates
Financial estimateRevenue estimate
Valuation estimate
TEMISIS leadership team
Management profileNumber of profiles
TEMISIS funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TEMISIS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TEMISIS
What does TEMISIS do?
Temisis Therapeutics is a pre-clinical biotechnology company developing proprietary small-molecule drug candidates for the treatment of inflammatory diseases, with a primary focus on psoriasis. Its lead program, TEM1657, targets the Th17/23 axis through both topical and oral routes, offering rapid efficacy and a best-in-class safety profile compared to existing corticosteroids and oral treatments such as Apremilast.
Is TEMISIS a public or private company?
TEMISIS is a private company. It is classified as corporate owned and is currently operating.
When was TEMISIS founded?
TEMISIS was founded in 2017. It employs 1 to 10 people.
Where is TEMISIS based?
TEMISIS is headquartered in Vandoeuvre-lès-nancy, France, in the Europe region.
Who are TEMISIS's main competitors?
Broad incumbents on record are Amgen, AbbVie, Novartis and Bristol Myers Squibb. Direct peers are Aristea Therapeutics, AnaptysBio, Ventyx Biosciences, Aclaris Therapeutics and Dice Molecules. Sareum Holdings is listed as an emerging player.
Does TEMISIS have an API?
No public API is recorded for TEMISIS.
What industry is TEMISIS in?
TEMISIS's product category is Inflammatory Disease Therapeutics. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors), with a secondary code of HLAIAIAM, Rare Dermatology Disorder Therapies. Its NAICS code is 325411 and its SIC code is 2834.